Innate Pharma S.A. (IPHA)

Market Cap	192.71M
Revenue (ttm)	36.20M
Net Income (ttm)	-36.49M
Shares Out	80.95M
EPS (ttm)	-0.45
PE Ratio	n/a
Forward PE	7.05
Dividend	n/a
Ex-Dividend Date	n/a

Volume	116,557
Open	2.260
Previous Close	2.210
Day's Range	2.160 - 2.260
52-Week Range	1.290 - 3.511
Beta	0.79
Analysts	Strong Buy
Price Target	11.50 (+413.39%)
Earnings Date	Mar 20, 2025

About IPHA

Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head an...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 17, 2019
• Employees: 179
• Stock Exchange: NASDAQ
• Ticker Symbol: IPHA
• Website: https://www.innate-pharma.com

Financial Performance

In 2023, Innate Pharma's revenue was 61.64 million, an increase of 6.88% compared to the previous year's 57.67 million. Losses were -7.57 million, -86.97% less than in 2022.

Financial numbers in EUR

Analyst Forecast

According to one analyst, the rating for IPHA stock is "Strong Buy" and the 12-month stock price forecast is $11.5.

Price Target

$11.5

(413.39% upside)

Analyst Consensus: Strong Buy